Castration-resistant prostate cancer (CRPC) represents a final stage of this malignancy for many men and is defined as the progression of prostate cancer despite castrate levels of testosterone. CRPC may present as a rising PSA, the development of new metastases, or worsening of known metastases. Recent advances have resulted in five new treatments for CRPC: the immunotherapy sipuleucel-T; the cytotoxic cabazitaxel; the androgen biosynthesis inhibitor abiraterone acetate; the radioisotope radium-223; and the antiandrogen enzalutamide. These have all improved overall survival in randomized phase III studies for patients with metastatic CRPC. Furthermore, multiple agents and combinations are currently in late-stage clinical testing. Men with advanced prostate cancer represent an important population for clinical and translational research and clinical trial participation should be considered as part of standard care.
Era 223—A Phase 3 Trial of Radium-223 Dichloride (Ra-223) in Combination with Abiraterone Acetate (Aa) and Prednisone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with Bone-Predominant Metastatic Castration-Resistant Prostate Cancer (Crpc)
